1 Blau N, FJ van Spronsen, Levy HL. Phenylketonuria. The Lancet 2010;376: 1417-27.
2 Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338–43.
3 Chen RG, Chen HY, Shi SZ, Bai NQ, Ding XJ, Ding Y, et al. Preliminary report on neonatal screening for hypothyroidism, phenylketonuria and galactosemia. Shanghai Medical Journal1983;6:344-6.
4 Shi XT, Cai J, Wang YY, Tu WJ, Wang WP, Gong LM, et al. Newborn screening for inborn errors of metabolism in mainland China: 30 years of experience. JIMD Rep 2012;6:79-83.
5 Mei L, Song P, Xu L. Newborn screening and related policy against Phenylketonuria in China. Intractable Rare Dis Res 2013; 2:72-6.
6 Shen M. Paying more attention to the prevention and treatment of maternal phenylketonuria. Chin J Appl Clin Pediatr 2016;31(20):1521-24.
7 Lenke RR, Levy HL. Maternal phenylketonuria and hyperphenylalaninemia: an international survey of the outcome of untreated and treated pregnancies. N Engl J Med 1980;303:1202–8.
8 Koch R, Hanley W, Levy H, Matalon K, Matalon R, Rouse B, et al. The maternal phenylketonuria international study: 1984–2002. Pediatrics2003;112:1523–99.
9 Widaman KF, Azen C. Relation of prenatal phenylalanine exposure to infant and childhood cognitive outcomes: results from the international maternal PKU collaborative study. Pediatrics 2003;112:1537–43.
10 Langendonk JG, Roos JC, Angus L, Williams M, Karstens FP, de Klerk JB,et al.A series of pregnancies in women with inherited metabolic disease. J Inherit Metab Dis 2012;35:419–24.
11 Andersson HC. 50 Years ago in The Journal of Pediatrics: Children of mothers with phenylketonuria. Pediatrics 2013;163:671.
12 Maillot F, Lilburn M, Baudin J, Morley DW, Lee PJ. Factors influencing outcomes in the off spring of mothers with phenylketonuria during pregnancy: the importance of variation in maternal blood phenylalanine. Am J Clin Nutr 2008;88:700–5.
13 Liu YP, Wang Q, Li XY, Ding Y, Song JQ, Yang YL. First Chinese case of successful pregnancy with combined methylmalonicaciduria and homocystinuria, cblC type. Brain & Development 2015;37:286–91.
14 Conoley JC, Impera JC. Gesell Child Developmental Age Scale. The Twelfth Mental Measurements Yearbook.1995.
15 Aubard Y, Darodes N, Cantaloube M. Hyperhomocysteinemia and pregnancy – review of our present understanding and therapeutic implications. Eur J Obstet Gyncol Reprod Biol 2000;93:157–65.
16 Levy HL. Historical background for the maternal PKU syndrome. Pediatrics2003; 112:1516-8.
17 Rausell D, García-Blanco A, Correcher P, Vitoria I, Vento M, Cháfer-Pericás C. Newly validated biomarkers of brain damage may shed light into the role of oxidative stress in the pathophysiology of neurocognitive impairment in dietary restricted phenylketonuria patients. Pediatric research. 2019 Jan;85(2):242-50.
18 Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipcic-Schmidt S, de la Cruz F, Hall R, Matalon R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA. 2000 Feb 9;283(6):756-62.
19 Rouse B, Azen C. Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: The importance of strict dietary control preconception and throughout pregnancy. J Pediatr 2004;144(2):235–239. doi:10.1016/j.jpeds.2003.10.062.
20 Platt LD, Koch R, Hanley WB, Lew HL, Matalon R, Rouse B, et al. The International Study of Pregnancy Outcome in Women with Maternal Phenylketonuria: Report of a 12 year Study. Am J Obstet Gynecol 2000;182:326–33.
21 Wang L, Zou H, Ye F, Wang KD, Li XW, Chen ZH, et al. Household financial burden of phenylketonuria treatment in China: a cross-sectional study. J Inherit Metab Dis 2017;40:369-76.
22 Moseley K, Skrabal J, Yano S,Koch R. Sapropterindihydrochloride (6R-BH4) and maternal phenylketonuria: two case studies[J]. Infant Child Adolesc Nutr 2009;1: 262–6.
23 Aldámiz-Echevarría L, Couce ML, Llarena M, Andrade F. A new case of maternal phenylketonuria treated with sapropterindihydrochloride (6R-BH4). Gynecol Endocrinol 2014;30:691–3.
24 Feillet F, Ficicioglu C, Lagler FB, et al.An Interim Analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) and Phenylketonuria Developmental Outcomes and Safety (PKU MOMs) Registries: Pregnancies. Presented at the 13th International Congress of Inborn Errors of Metabolism: September 5-8, 2017, Rio de Janeiro, Brazil.